Globus Medical Pre-Tax Profit Margin 2010-2022 | GMED

Current and historical pre-tax profit margin for Globus Medical (GMED) from 2010 to 2022. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue. Globus Medical pre-tax profit margin for the three months ending September 30, 2022 was .
Globus Medical Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2022-09-30 $1.00B $0.20B 20.12%
2022-06-30 $0.98B $0.19B 19.90%
2022-03-31 $0.96B $0.17B 17.88%
2021-12-31 $0.96B $0.18B 18.79%
2021-09-30 $0.94B $0.22B 23.59%
2021-06-30 $0.93B $0.22B 23.84%
2021-03-31 $0.83B $0.15B 18.18%
2020-12-31 $0.79B $0.13B 15.84%
2020-09-30 $0.77B $0.12B 15.23%
2020-06-30 $0.75B $0.11B 14.84%
2020-03-31 $0.79B $0.18B 22.67%
2019-12-31 $0.79B $0.19B 24.17%
2019-09-30 $0.77B $0.18B 23.90%
2019-06-30 $0.74B $0.18B 24.23%
2019-03-31 $0.72B $0.18B 25.38%
2018-12-31 $0.71B $0.19B 26.54%
2018-09-30 $0.69B $0.19B 27.75%
2018-06-30 $0.68B $0.19B 27.56%
2018-03-31 $0.65B $0.18B 26.91%
2017-12-31 $0.64B $0.17B 26.73%
2017-09-30 $0.61B $0.16B 25.33%
2017-06-30 $0.60B $0.16B 26.34%
2017-03-31 $0.58B $0.16B 26.68%
2016-12-31 $0.56B $0.16B 27.84%
2016-09-30 $0.56B $0.18B 31.89%
2016-06-30 $0.56B $0.18B 32.19%
2016-03-31 $0.55B $0.18B 32.19%
2015-12-31 $0.55B $0.17B 31.50%
2015-09-30 $0.53B $0.16B 29.14%
2015-06-30 $0.51B $0.15B 29.04%
2015-03-31 $0.49B $0.14B 29.21%
2014-12-31 $0.48B $0.14B 29.05%
2014-09-30 $0.46B $0.13B 28.42%
2014-06-30 $0.45B $0.13B 28.00%
2014-03-31 $0.44B $0.11B 23.70%
2013-12-31 $0.43B $0.10B 23.73%
2013-09-30 $0.42B $0.10B 23.81%
2013-06-30 $0.41B $0.10B 23.77%
2013-03-31 $0.40B $0.12B 29.22%
2012-12-31 $0.39B $0.11B 29.46%
2012-09-30 $0.37B $0.11B 29.14%
2012-06-30 $0.36B $0.11B 29.75%
2012-03-31 $0.35B $0.10B 29.31%
2011-12-31 $0.33B $0.10B 29.31%
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $7.506B $0.958B
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company currently has its sales operations distributed across counties world wide. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and unique surgical instruments, used in an expansive range of spinal, orthopedic and neurosurgical procedures. The spine products address the vast majority of conditions affecting the spine including degenerative conditions, deformity, tumors and trauma. Enabling Technologies are designed to enhance a surgeon's capabilities and streamline the complicated surgical procedures to be safer, less invasive, accurate and more reproducible to improve patient care and reduce radiation exposure for both patient and caregiver. The technology contains imaging, navigation and robotic assisted surgery solutions. It acquired all assets of StelKast, Inc. and Finnish engineering company Synoste Oy.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $226.442B 23.68
Edwards Lifesciences (EW) United States $48.354B 33.28
Alcon (ALC) Switzerland $36.722B 31.62
STERIS (STE) Ireland $20.456B 25.46
Teleflex (TFX) United States $11.305B 18.34
Fresenius Medical Care AG KGaA (FMS) Germany $10.584B 10.62
Penumbra (PEN) United States $9.289B 2223.46
Integer Holdings (ITGR) United States $2.380B 19.11
Glaukos (GKOS) United States $2.298B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.402B 19.97
Paragon 28 (FNA) United States $1.303B 0.00
Nevro (NVRO) United States $1.291B 0.00
Artivion (AORT) United States $0.505B 0.00